Novel Therapeutic and Pathogenetic Studies of Oculomotor Disorders

The summary for the Novel Therapeutic and Pathogenetic Studies of Oculomotor Disorders grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Novel Therapeutic and Pathogenetic Studies of Oculomotor Disorders: The National Eye Institute (NEI) encourages the submission of investigator- initiated applications to develop novel therapeutic and pathogenetic approaches to disorders that affect ocular motility. These disorders include strabismus syndromes, myasthenia gravis, congenital fibrosis syndromes, congenital nystagmus, and other disorders that compromise eye movement in the orbit and thus limit visual acuity. Many of these disorders, such as strabismus, are common in childhood and can lead to permanent visual loss if uncorrected. Present treatments are largely surgical in nature, with uneven success and the need for repeated surgery. Therapy for symptoms such as pain, pressure, or double vision present in some disorders is solely palliative in nature. The mechanisms of pathogenesis for these disorders is largely unknown. Responses to this announcement may include applications for basic or applied, preclinical or clinical research. Applications may broadly address novel therapeutic strategies and/or new insights into the pathogenesis of oculomotor diseases.
Federal Grant Title: Novel Therapeutic and Pathogenetic Studies of Oculomotor Disorders
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-EY-03-001
Type of Funding: Grant
CFDA Numbers: 93.867
CFDA Descriptions: Vision Research
Current Application Deadline: No deadline provided
Original Application Deadline: March 27, 2003, and November 21, 2003
Posted Date: Aug 04, 2003
Creation Date: Dec 21, 2003
Archive Date: Dec 21, 2003
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Individuals For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
Webmaster, NIH, Webmaster, Phone not available, Fax not available, Email Webmaster, NIH
Similar Government Grants
NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integ...
Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional)
NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed)
NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allo...
NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
Nei Career Transition Award (K22)
NEI Translational Research Program On Therapy For Visual Disorders
NEI Clinical Study Planning Grant Program (R34)
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021